Novation awards 33 cardiovascular contracts

Novation, a healthcare contracting services provider of the healthcare alliances VHA and the University HealthSystem Consortium, has awarded 33 multi-source agreements for cardiovascular products in its cardiovascular portfolio. The Irving, Texas-based Novation said it could provide up to $267 million in savings for alliance member hospitals.

The 33 contracts were awarded to 13 companies, and the agreements take effect Oct. 1 through Sept. 30, 2010.

The companies that received the contracts are: Abbott Vascular; Bard EP and Bard Peripheral; Boston Scientific; Cardiva Medical; ev3; Marine Polymer; Merit Medical; Medtronic; Terumo; and TZ Medical.

The product categories include electrophysiology; percutaneous coronary intervention; coronary diagnostic; vascular closure devices; peripheral interventional; peripheral diagnostic; thrombus management; neuro interventional and cardiac rhythm management.

Around the web

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.